Tags

Type your tag names separated by a space and hit enter

[New triptan preparations can help the migraine patient. Pharmacodynamic and pharmacokinetic progresses].
Lakartidningen. 1998 Nov 11; 95(46):5175, 5178-82, 5184-6.L

Abstract

Migraine is an idiopathic, recurrent neurovascular headache disorder characterised by attacks of debilitating pain associated with photophobia, phonophobia, nausea and vomiting. It is apparently a global disorder, occurring in all races, cultures and geographical locations. Migraine has a hereditary component, and its life-time prevalence is about 16%. About a third of migraine patients in Sweden seem to be particularly sorely afflicted having 1-6 severe attacks a month and accounting for more than 80 per cent of the annual total of about 14 million attacks in the country as a whole. In general, these migraine sufferers do not obtain satisfactory relief from simple analgesice or NSAIDs (non-sterodial antiinflammatory drugs only), and thus require additional migraine-specific treatment. Selective 5-HT1B/1D-agonists, the so-called triptans, have become an invaluable addition to the therapeutic arsenal for treating this category of patients.

Authors+Show Affiliations

Migränklinik-Göteborg.

Pub Type(s)

English Abstract
Journal Article
Review

Language

swe

PubMed ID

9842191

Citation

Dahlöf, C G.. "[New Triptan Preparations Can Help the Migraine Patient. Pharmacodynamic and Pharmacokinetic Progresses]." Lakartidningen, vol. 95, no. 46, 1998, pp. 5175, 5178-82, 5184-6.
Dahlöf CG. [New triptan preparations can help the migraine patient. Pharmacodynamic and pharmacokinetic progresses]. Lakartidningen. 1998;95(46):5175, 5178-82, 5184-6.
Dahlöf, C. G. (1998). [New triptan preparations can help the migraine patient. Pharmacodynamic and pharmacokinetic progresses]. Lakartidningen, 95(46), 5175, 5178-82, 5184-6.
Dahlöf CG. [New Triptan Preparations Can Help the Migraine Patient. Pharmacodynamic and Pharmacokinetic Progresses]. Lakartidningen. 1998 Nov 11;95(46):5175, 5178-82, 5184-6. PubMed PMID: 9842191.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [New triptan preparations can help the migraine patient. Pharmacodynamic and pharmacokinetic progresses]. A1 - Dahlöf,C G, PY - 1998/12/8/pubmed PY - 1998/12/8/medline PY - 1998/12/8/entrez SP - 5175, 5178-82, 5184-6 JF - Lakartidningen JO - Lakartidningen VL - 95 IS - 46 N2 - Migraine is an idiopathic, recurrent neurovascular headache disorder characterised by attacks of debilitating pain associated with photophobia, phonophobia, nausea and vomiting. It is apparently a global disorder, occurring in all races, cultures and geographical locations. Migraine has a hereditary component, and its life-time prevalence is about 16%. About a third of migraine patients in Sweden seem to be particularly sorely afflicted having 1-6 severe attacks a month and accounting for more than 80 per cent of the annual total of about 14 million attacks in the country as a whole. In general, these migraine sufferers do not obtain satisfactory relief from simple analgesice or NSAIDs (non-sterodial antiinflammatory drugs only), and thus require additional migraine-specific treatment. Selective 5-HT1B/1D-agonists, the so-called triptans, have become an invaluable addition to the therapeutic arsenal for treating this category of patients. SN - 0023-7205 UR - https://www.unboundmedicine.com/medline/citation/9842191/[New_triptan_preparations_can_help_the_migraine_patient__Pharmacodynamic_and_pharmacokinetic_progresses]_ L2 - http://www.diseaseinfosearch.org/result/4811 DB - PRIME DP - Unbound Medicine ER -